{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:40:24Z","timestamp":1791819624739,"version":"4.3.4"},"reference-count":14,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jaad.2025.06.058","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T11:23:00Z","timestamp":1754997780000},"page":"1035-1041","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Systemic risk profiles of topical ruxolitinib and oral Janus kinase inhibitors in patients with atopic dermatitis: A retrospective cohort study from the TriNetX network"],"prefix":"10.1016","volume":"93","author":[{"given":"Katherine","family":"Benandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Spires","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Linfante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1642","key":"10.1016\/j.jaad.2025.06.058_bib1","first-page":"12","article-title":"Ruxolitinib (Opzelura) for atopic dermatitis","volume":"64","year":"2022","journal-title":"Med Lett Drugs Ther"},{"issue":"4","key":"10.1016\/j.jaad.2025.06.058_bib2","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s40257-021-00610-x","article-title":"Pharmacokinetics of ruxolitinib in patients with atopic dermatitis treated with ruxolitinib cream: data from phase II and III studies","volume":"22","author":"Gong","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2025.06.058_bib3","series-title":"FDA Guidance Document: warnings and precautions section of labeling for human prescription drug and biological products \u2014 content and format","year":"2011"},{"issue":"3","key":"10.1016\/j.jaad.2025.06.058_bib4","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s13555-023-00892-5","article-title":"A review on the safety of using JAK inhibitors in dermatology: clinical and laboratory monitoring","volume":"13","author":"Samuel","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"10.1016\/j.jaad.2025.06.058_bib5","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/1744666X.2022.2014323","article-title":"The infection risks of JAK inhibition","volume":"18","author":"Adas","year":"2022","journal-title":"Expert Rev Clin Immunol"},{"issue":"12","key":"10.1016\/j.jaad.2025.06.058_bib6","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1177\/0091270010389469","article-title":"The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers","volume":"51","author":"Shi","year":"2011","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.jaad.2025.06.058_bib7","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s40257-022-00690-3","article-title":"A maximum-use trial of ruxolitinib cream in adolescents and adults with atopic dermatitis","volume":"23","author":"Bissonnette","year":"2022","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2025.06.058_bib8","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","article-title":"Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from 2 phase 3, randomized, double-blind studies","volume":"85","author":"Papp","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2025.06.058_bib9","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J R Stat Soc Ser B (Methodological)"},{"issue":"9","key":"10.1016\/j.jaad.2025.06.058_bib11","first-page":"532","article-title":"Dupilumab (dupixent): an interleukin-4 receptor antagonist for atopic dermatitis","volume":"43","author":"D'Ippolito","year":"2018","journal-title":"P T"},{"key":"10.1016\/j.jaad.2025.06.058_bib12","series-title":"Prior authorization and notification policy for dupixent (dupilumab). UnitedHealthcare","year":"2023"},{"issue":"1","key":"10.1016\/j.jaad.2025.06.058_bib13","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s40278-016-21372-5","article-title":"FDA committee recommends removing warning","volume":"1620","year":"2016","journal-title":"React Wkly"},{"issue":"1","key":"10.1016\/j.jaad.2025.06.058_bib14","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s13555-021-00638-1","article-title":"Dupilumab with topical corticosteroids provides rapid and sustained improvement in adults with moderate-to-severe atopic dermatitis across anatomic regions over 52 weeks","volume":"12","author":"Blauvelt","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"5","key":"10.1016\/j.jaad.2025.06.058_bib15","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s40257-022-00712-0","article-title":"What's new in topicals for atopic dermatitis?","volume":"23","author":"Kleinman","year":"2022","journal-title":"Am J Clin Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225023886?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962225023886?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T12:20:18Z","timestamp":1758198018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962225023886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":14,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0190962225023886"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2025.06.058","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic risk profiles of topical ruxolitinib and oral Janus kinase inhibitors in patients with atopic dermatitis: A retrospective cohort study from the TriNetX network","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2025.06.058","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}